EIKN · Eikon Therapeutics, Inc. · Investor Relations

$5.90 +0.06 (+1.03%) At close · Nov 6

Russell 2000 member Rebalance outlook locked

Market Cap

$319.57M

54.17M

Volume · Nov 6 402.39K Avg daily vol (3M) 576.61K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date	Event	Type
2026-11-10 13:00 UTC	Guggenheim 3rd Annual Healthcare Innovation Conference	Conference

Recent news

Date	Headline
2026-10-26	Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
2026-10-23	Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
2026-08-13	Eikon Therapeutics Reports Second Quarter 2026 Financial Results
2026-06-01	Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
2026-05-11	Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
2026-03-30	Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

Past events

Date	Event	Type
2026-11-06	JP Morgan Biotech Call Series	Webcast
2026-11-03	Post-ESMO: New Data & the Evolving Synthetic Lethality Landscape	Webcast
2026-09-15	Morgan Stanley 24th Annual Global Healthcare Conference	Conference
2026-09-10	12th Annual Cantor Global Healthcare Conference	Conference
2026-08-20	KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald	Event

Source: https://investors.eikontx.com/

Key facts CIK 1861123 CUSIP 282564103 13F (30d) 28 filings 28 filers Visit website Investor relations